The correlative studies indicated that high AURKA registration tumor expression was associated with poor clinical outcomes, which was consistent with prior studies.9,30 Additional correlative studies are under way to evaluate the role of PIK3CA variant status and assess whether pharmacodynamic-induced changes in ERα, total and phosphorylated AURKA, and other stemness biomarkers that are associated with clinical benefit from alisertib. Here, ESR1 is linked to neoplasm.